Literature DB >> 16169518

Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.

Young-Rae Lee1, Jinny Park, Hong-Nu Yu, Jong-Suk Kim, Hyun Jo Youn, Sung Hoo Jung.   

Abstract

Estrogen stimulates cell proliferation in breast cancer. The biological effects of estrogen are mediated through two intracellular receptors, estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta). However, the role of ERs in the proliferative action of estrogen is not well established. Recently, it has been known that ER activates phosphatidylinositol-3-OH kinase (PI3K) through binding with the p85 regulatory subunit of PI3K. Therefore, possible mechanisms may include ER-mediated phosphoinositide metabolism with subsequent formation of phosphatidylinositol-3,4,5-trisphosphate (PIP(3)), which is generated from phosphatidylinositol 4,5-bisphosphate via PI3K activation. The present study demonstrates that 17beta-estradiol (E2) up-regulates PI3K in an ERalpha-dependent manner, but not ERbeta, and stimulates cell growth in breast cancer cells. In order to study this phenomenon, we have treated ERalpha-positive MCF-7 cells and ERalpha-negative MDA-MB-231 cells with 10nM E2. Treatment of MCF-7 cells with E2 resulted in a marked increase in PI3K (p85) expression, which paralleled an increase in phospho-Akt (Ser-473) and PIP(3) level. These observations also correlated with an increased activity to E2-induced cell proliferation. However, these effects of E2 on breast cancer cells were not observed in the MDA-MB-231 cell line, indicating that the E2-mediated up-regulation of PI3K/Akt pathway is ERalpha-dependent. These results suggest that estrogen activates PI3K/Akt signaling through ERalpha-dependent mechanism in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169518     DOI: 10.1016/j.bbrc.2005.08.256

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Authors:  Stephanie J Byer; Jenell M Eckert; Nicole M Brossier; Buffie J Clodfelder-Miller; Amy N Turk; Andrew J Carroll; John C Kappes; Kurt R Zinn; Jeevan K Prasain; Steven L Carroll
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

Review 2.  Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome.

Authors:  Andrea L Hevener; Deborah J Clegg; Franck Mauvais-Jarvis
Journal:  Mol Cell Endocrinol       Date:  2015-05-29       Impact factor: 4.102

3.  Silencing of ZRF1 impedes survival of estrogen receptor positive MCF-7 cells and potentiates the effect of curcumin.

Authors:  Sandip Kumar Rath; Moonmoon Deb; Dipta Sengupta; Vijayalaxmi Kari; Swayamsiddha Kar; Sabnam Parbin; Nibedita Pradhan; Samir Kumar Patra
Journal:  Tumour Biol       Date:  2016-06-27

4.  Allicin inhibits the invasion of lung adenocarcinoma cells by altering tissue inhibitor of metalloproteinase/matrix metalloproteinase balance via reducing the activity of phosphoinositide 3-kinase/AKT signaling.

Authors:  Ling Huang; Yuanhong Song; Jianping Lian; Zhiwei Wang
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

5.  Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.

Authors:  Velusamy Rangasamy; Rajakishore Mishra; Suneet Mehrotra; Gautam Sondarva; Rajarshi S Ray; Arundhati Rao; Malay Chatterjee; Basabi Rana; Ajay Rana
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

6.  SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.

Authors:  Yuanzhong Wang; Dujin Zhou; Sheryl Phung; Selma Masri; David Smith; Shiuan Chen
Journal:  Mol Endocrinol       Date:  2010-11-17

7.  Calmodulin modulates Akt activity in human breast cancer cell lines.

Authors:  Christine M Coticchia; Chetana M Revankar; Tushar B Deb; Robert B Dickson; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2008-06-28       Impact factor: 4.872

8.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

9.  Membrane estrogen receptor-alpha interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats.

Authors:  Phoebe Dewing; Marissa I Boulware; Kevin Sinchak; Amy Christensen; Paul G Mermelstein; Paul Micevych
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

Review 10.  ERbeta in breast cancer--onlooker, passive player, or active protector?

Authors:  Emily M Fox; Rebecca J Davis; Margaret A Shupnik
Journal:  Steroids       Date:  2008-04-20       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.